MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2026-06-22		NCT04555551

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Memorial Sloan Kettering Cancer Center	753

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	United States	131
Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	United States	184
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	United States	186
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	United States	120
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack	United States	55
Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	United States	166